×
0 -0.002442748091603 0.0458015267175573 0.0687022900763359 0.144198473282443 0.183206106870229 0.183206106870229 0.225190839694656
Stockreport

Sage Therapeutics' SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarket [Seeking Alpha]

SAGE THERAPEUTICS (SAGE)  More Company Research Source: Seeking Alpha
Last sage therapeutics earnings: 11/2 06:30 am Check Earnings Report
PDF NASDAQ-NMS:SAGE Sage Therapeutics' SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarketNASDAQ-NMS:SAGE Sage Therapeutics (NASDAQ:SAGE) is up52% premarket on light volume in response to itsannouncement of positive results from a Phase 2 [Read more]

IMPACT SNAPSHOT EVENT TIME: SAGE
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS